[Poseidonol in the treatment of hyperlipidemia in patients with type 2 diabetes mellitus].
Thirty five patients with type 2 diabetes mellitus complicated by cardiovascular diseases received 6-month treatment for hyperlipidemia with poseidonol that represents a set of essential polyunsaturated fatty acids. This yielded good results as 11.6%-, 30%- and 24.2% decreases in the levels of cholesterol, triglycerides, and beta-lipoprotein, respectively, and a 9.9%- increase in alpha-lipoprotein. Lipid metabolism became normal in 34.2% of the patients, the remaining had positive changes as normalization of 1 to 3 lipid parameters. The tolerance of the agent was good, no negative effect on hepatic and renal functions was found.
Panchenko
V M
VM
Ershov
A A
AA
Isaev
V A
VA
ZImovchenko
G S
GS
Chernova
G I
GI
D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004338:Drug Combinations; D005228:Fatty Acids, Essential / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications* / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014815:Vitamins / Q000008:administration & dosage / Q000627:therapeutic use*
D004338:Drug Combinations; D005228:Fatty Acids, Essential; D000960:Hypolipidemic Agents; D014815:Vitamins
Poseĭdonol v lechenii giperlipidemii u bol'nykh sakharnym diabetom tipa 2.